NCT04662619View on ClinicalTrials.gov

A Study of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis

NACompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

December 7, 2023

Study Completion Date

November 19, 2024

Conditions
Healthy
Interventions
OTHER

B. infantis

"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks."

OTHER

Lactose Placebo

Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.

Trial Locations (1)

00290

HUS Children and Adolescents, Clinical Trial Unit, Park Hospital, Helsinki

All Listed Sponsors
collaborator

Infinant Health, Inc. (formerly known as Evolve BioSystems, Inc.)

UNKNOWN

lead

Johnson & Johnson Consumer Inc. (J&JCI)

INDUSTRY

NCT04662619 - A Study of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis | Biotech Hunter | Biotech Hunter